Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (2391)	12/11/1998 8:04:00 PM
From: jim webster	Read Replies (1) \| Respond to of 4676

I would like to know if the interim analysis on 2302 is successful, would it be possible if FDA approval would be in mid 99'? Another way to say is: Could Isis stop the trial early and go straight to FDA? Is there any biotech clinical analysts that would know that answer, if so that would make ISIS a $100 stock. I would love to see the shorts get squeezed out at triple digits. I can hear them squealing in Texas. This is an early warning to the shorts to start covering while they still can. Jim